Literature DB >> 7805185

Effects of storage on the binding of carboplatin to plasma proteins.

K Erkmen1, M J Egorin, L M Reyno, R Morgan, J H Doroshow.   

Abstract

Plasma ultrafiltrates are routinely used in pharmacokinetic studies of carboplatin. Experiments were performed to detect and quantitate artifactual decreases in the platinum concentration of ultrafiltrates prepared from plasma samples stored at -20 degrees C and -70 degrees C. Carboplatin was added to anticoagulated, whole human blood to produce a 20 microgram/ml concentration. Plasma produced from the blood was stored frozen at either -20 degrees C or -70 degrees C. Aliquots from each storage condition were thawed and ultrafiltered once a week for up to 100 days. Platinum concentrations in ultrafiltrates and plasma were determined by flameless atomic absorption spectrometry. There was no loss of ultrafilterable platinum in plasma samples stored at -70 degrees C, whereas there was a steady decrease in free platinum concentration in ultrafiltrates prepared from plasma samples stored at -20 degrees C. These results imply that pharmacokinetic studies of carboplatin should use ultrafiltrates prepared immediately or that plasma for such studies should be stored at -70 degrees C. Storage of carboplatin-containing plasma at -20 degrees C and subsequent ultrafiltration is not acceptable, because measurement of platinum in such ultrafiltrates will be artifactually low.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7805185     DOI: 10.1007/BF00686557

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  20 in total

1.  Protein binding of five platinum compounds. Comparison of two ultrafiltration systems.

Authors:  W J van der Vijgh; I Klein
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  In vitro stability, plasma protein binding and blood cell partitioning of 14C-carboplatin.

Authors:  R C Gaver; A M George; G Deeb
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  A limited sampling method for estimation of the carboplatin area under the curve.

Authors:  B T Sørensen; A Strömgren; P Jakobsen; A Jakobsen
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

4.  A program package for simulation and parameter estimation in pharmacokinetic systems.

Authors:  D Z D'Argenio; A Schumitzky
Journal:  Comput Programs Biomed       Date:  1979-03

5.  Complexes of serum albumin and cis-dichlorodiammineplatinum (II). The role of cysteine 34 as a nucleophilic entering group and evidence for reaction between bound platinum and a second macromolecule.

Authors:  S L Gonias; S V Pizzo
Journal:  J Biol Chem       Date:  1983-05-10       Impact factor: 5.157

Review 6.  Clinical pharmacokinetics of carboplatin.

Authors:  W J van der Vijgh
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

7.  Kinetics of cis-dichlorodiammineplatinum.

Authors:  P E Gormley; J M Bull; A F LeRoy; R Cysyk
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

8.  Pharmacokinetic study of cis-dichlorodiammineplatinum(II) (DDP) in the beagle dog: thermodynamic and kinetic behavior of DDP in a biologic millieu.

Authors:  A F LeRoy; R J Lutz; R L Dedrick; C L Litterst; A M Guarino
Journal:  Cancer Treat Rep       Date:  1979-01

9.  Serial determination of platinum, protein content and free sulfhydryl levels in plasma of patients treated with cisplatin or carboplatin.

Authors:  F Tosetti; M Rocco; R A Fulco; S Chiara; M Bruzzone; E Campora; M Esposito
Journal:  Anticancer Res       Date:  1988 May-Jun       Impact factor: 2.480

10.  Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer.

Authors:  L M Reyno; M J Egorin; R M Canetta; D I Jodrell; K D Swenerton; J L Pater; J N Burroughs; M J Novak; R Sridhara
Journal:  J Clin Oncol       Date:  1993-06       Impact factor: 44.544

View more
  9 in total

1.  In vitro circuit stability of 5-fluorouracil and oxaliplatin in support of hyperthermic isolated hepatic perfusion.

Authors:  Heidi Colville; Ryan Dzadony; Rebecca Kemp; Stephen Stewart; Herbert J Zeh; David L Bartlett; Julianne Holleran; Kevin Schombert; Juliann E Kosovec; Merrill J Egorin; Jan H Beumer
Journal:  J Extra Corpor Technol       Date:  2010-03

2.  A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors.

Authors:  Margaret E Macy; Tracey Duncan; James Whitlock; Stephen P Hunger; Jessica Boklan; Aru Narendren; Cynthia Herzog; Robert J Arceci; Rochelle Bagatell; Tanya Trippett; Uwe Christians; Katherine Rolla; S Percy Ivy; Lia Gore
Journal:  Pediatr Blood Cancer       Date:  2012-09-28       Impact factor: 3.167

3.  Effect of hyperthermia in combination with TRAIL on the JNK-Bim signal transduction pathway and growth of xenograft tumors.

Authors:  Marco A Alcala; Kyungsoo Park; Jinsang Yoo; Dae-Hee Lee; Bae-Hang Park; Byeong-Chel Lee; David L Bartlett; Yong J Lee
Journal:  J Cell Biochem       Date:  2010-08-01       Impact factor: 4.429

4.  Genetically engineered cancer models, but not xenografts, faithfully predict anticancer drug exposure in melanoma tumors.

Authors:  Austin J Combest; Patrick J Roberts; Patrick M Dillon; Katie Sandison; Suzan K Hanna; Charlene Ross; Sohrab Habibi; Beth Zamboni; Markus Müller; Martin Brunner; Norman E Sharpless; William C Zamboni
Journal:  Oncologist       Date:  2012-09-19

5.  Enhancement of cisplatin [cis-diammine dichloroplatinum (II)] cytotoxicity by O6-benzylguanine involves endoplasmic reticulum stress.

Authors:  Cara A Rabik; Melissa L Fishel; Julianne L Holleran; Kristen Kasza; Mark R Kelley; Merrill J Egorin; M Eileen Dolan
Journal:  J Pharmacol Exp Ther       Date:  2008-07-29       Impact factor: 4.030

6.  Embryonic stem cells lacking the epigenetic regulator Cfp1 are hypersensitive to DNA-damaging agents and exhibit decreased Ape1/Ref-1 protein expression and endonuclease activity.

Authors:  Courtney M Tate; Melissa L Fishel; Julianne L Holleran; Merrill J Egorin; David G Skalnik
Journal:  DNA Repair (Amst)       Date:  2009-10-15

7.  Interstitial continuous infusion therapy in a malignant glioma model in rats.

Authors:  Yuichi Tange; Akihide Kondo; Merrill J Egorin; Barbara Mania-Farnell; Georgy M Daneriallis; Hiromichi Nakazaki; Simone T Sredni; Veena Rajaram; Stewart Goldman; Marcelo B Soares; Tadanori Tomita
Journal:  Childs Nerv Syst       Date:  2009-02-11       Impact factor: 1.475

8.  Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine.

Authors:  Smitha S Krishnamurthi; Joanna M Brell; Charles L Hoppel; Merrill J Egorin; Karen C Weaver; Xiaolin Li; Stephen T Ingalls; Eleanor G Zuhowski; Mark D Schluchter; Afshin Dowlati; Matthew M Cooney; Joseph Gibbons; Beth A Overmoyer; S Percy Ivy; Scot C Remick
Journal:  Cancer Chemother Pharmacol       Date:  2008-04-15       Impact factor: 3.333

9.  Long-term platinum retention after treatment with cisplatin and oxaliplatin.

Authors:  Elke E M Brouwers; Alwin D R Huitema; Jos H Beijnen; Jan H M Schellens
Journal:  BMC Clin Pharmacol       Date:  2008-09-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.